癌症研究
抗体-药物偶联物
靶向治疗
曲妥珠单抗
药品
计算生物学
医学
肿瘤科
药理学
内科学
生物
抗体
癌症
单克隆抗体
免疫学
乳腺癌
作者
Jiawei Zhou,Hanqing He,Shuhang Wang,Ning Li
出处
期刊:Med
[Elsevier]
日期:2024-03-01
卷期号:5 (3): 173-175
标识
DOI:10.1016/j.medj.2024.01.001
摘要
We analyzed the potential of HER2-targeted antibody-drug conjugates (ADCs) in treating NSCLC with activating HER2 mutations. We identified specific mutations, notably G776delinsVC, that are associated with higher therapeutic response rates, suggesting a refined approach for precision treatment. Further validation and exploration are crucial for potential breakthroughs in ADC therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI